Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus
Lunai Bioworks Inc. has wrapped up a $20 million preferred-stock deal, securing CNS drug-delivery and neurotherapeutic IP in an effort to broaden its brain-disease lineup. The move, finalized May 1, also bolsters its case for Nasdaq equity compliance. Lunai disclosed the acquisition Monday.
TechStock² Updates
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
